Danish-American biotech company Genmab, which sold the global rights to its HuMax-CD20 antibody to GlaxoSmithKline for over DKK 12bn (USD 2.4bn) in 2007, is lining up to introduce another potential blockbuster, called HuMax-CD38, for the treatment of multiple myeloma (plasma cell cancer) writes financial daily newspaper Børsen.
If everything goes well in clinical development, Genmab estimates that it could have the product on the market in 3 or 4 years. Genmab's development director Claus Møller told Børsen that he reckons the market potential for HuMax-CD38 could be just as big as it is for HuMax-CD20, which generated revenues of USD 4bn in Europe and the US last year.
According to information on Genmab's website, multiple myeloma accounts for approximately 1% of all cancers. Approximately 11,000 deaths in the US each year are related to multiple myeloma and the estimated number of new cases is rising. At the present time there is no cure available.
Claus Møller sees a massive need for an antibody to add into existing treatment regimes, which can buy extra time for the patient but which are toxic to the body. "If one could increase remission time by supplementing existing treatment with a non-toxic alternative, there could be massive potential," says Møller.
Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, rheumatoid arthritis, infectious diseases and other inflammatory conditions.
Genmab is listed on the OMX Nordic Exchange Copenhagen.